



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Tian-Li WANG et al.) Group Art Unit: TBA
Serial No.: 10/588,237) Examiner: TBA
Filed: August 3, 2006)
For: Thymidylate Synthase Gene and Metastasis) Docket No. 001107.00606

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450


Dear Sir:

Submitted herewith are two (2) sheets of Form PTO-1449. A copy of each of the references listed therein is enclosed. It is respectfully requested that the Examiner make his/her consideration of each of these documents formally of record.

Since this Information Disclosure Statement is being filed before issuance of a first Office Action on the merits under 37 C.F.R. 1.97(b), it is submitted that no fee or certification is required. However, if a fee is required, please charge our deposit account no. 19-0733.


Respectfully submitted,

By:


Sarah A. Kagan
Registration No. 32,141

Dated: November 2, 2006

Banner & Witcoff, Ltd.
Customer No. 22907



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for FORM 1470

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/588,237
Filing Date	August 3, 2006
First Named Inventor	Tian-Li WANG, et al.
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 001107.00606

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Berger, Sondra H. et al., "Thymidylate Synthase Overproduction and Gene Amplification in Fluorodeoxyuridine-Resistant Human Cells," <i>Mol. Pharm.</i> 28:461-467	
		Clark, John L. et al., "Thymidylate Synthase Gene Amplification in a Colon Tumor Resistant to Fluoropyrimidine Chemotherapy," <i>Cancer Treat Rep.</i> 71:261-265, 1987	
		Copur, Sitki et al., "Thymidylate Synthase Gene Amplification in Human Colon Cancer Cell Lines Resistant to 5-Fluorouracil," <i>Biochemical Pharmacology</i> , Vol. 49, No. 10, pp. 1419-1426, 1995	
		Danenberg, Kathleen D. and Danenberg, Peter V. "Activity of Thymidylate Synthetase and its Inhibition by 5-Fluorouracil in Highly Enzyme-Overproducing Cells Resistant to 10-Propargyl-5, 8-Dideazafolate," <i>Molecular Pharmacology</i> , 36:219-223	
		Edler, David et al., "Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit from Adjuvant Fluorouracil-Based Chemotherapy," <i>J. Clin. Oncology</i> , Vol. 20, No. 7 (April 1), 2002: pp. 1721-1728	
		Findlay, MPN et al., "Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy," <i>British J. of Cancer</i> , (1997) 75(6), pp. 903-909	
		Johnston, Patrick G. et al., "Thymidylate Synthase Protein Expression in Primary Colorectal Cancer: Lack of Correlation with Outcome and Response to Fluorouracil in Metastatic Disease Sites," <i>J. Clin. Oncology</i> , Vol. 21, No. 5 (March 1), 2003: pp. 815-819	

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/588,237
Filing Date	August 3, 2006
First Named Inventor	Tian-Li WANG, et al.
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 001107.00606

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gorlick, Richard et al., "Higher Levels of Thymidylate Synthase Gene Expression are Observed in Pulmonary as Compared with Hepatic Metastases of Colorectal Adenocarcinoma," <i>J. Clin. Oncology</i> , Vol. 16, No. 4 (April), 1998: pp. 1465-1469	
		Johnston, Patrick G. et al., "Thymidylate Synthase Gene and Protein Expression Correlate and Are Associated with Response to 5-Fluorouracil in Human Colorectal and Gastric Tumors," <i>Can. Research</i> , 55, 1407-1412, April 1, 1995	
		Lenz, Heinz-Joseph et al., "p53 Point Mutations and Thymidylate Synthase Messenger RNA Levels in Disseminated Colorectal Cancer: An Analysis of Response and Survival," <i>Clin. Cancer Research</i> Vol. 4, pp. 1243-1250, May 1998	
		Lonn, Ulf et al., "Higher Frequency of Gene Amplification in Breast Cancer Patients Who Received Adjuvant Chemotherapy," <i>Cancer</i> , January 1, 1996, Vol. 77, No. 1, pp. 107-112	
		Neuteboom, Saskia T.C. et al., "Inhibition of Cell Growth by NB1011 Requires High Thymidylate Synthase Levels and Correlates with p53, p21, Bax, and GADD45 Induction," <i>Mol. Cancer Therapeutics</i> , Vol. 1, 377-384, April 2002	
		Spears, Colin Paul et al., "Mechanisms of Innate Resistance to Thymidylate Synthase Inhibition after 5-Fluorouracil," <i>Cancer Research</i> , 43, 5894-5900, October 15, 1988	

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231